T. Rowe Price Associates
TMBR

T. Rowe Price Associates’s Timber Pharmaceuticals, Inc. TMBR Stock Holding History

T. Rowe Price Associates’s Portfolio TMBR Stock Details TMBR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2,694
Closed -$123K – 3074
2021
Q3 		$123K Buy
2,694
+1,314
+95% +$64.4K ﹤0.01% 2809
2021
Q2 		$84K Buy
+1,380
New +$97K ﹤0.01% 2863

Other funds holding TMBR

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

T. Rowe Price Associates's TMBR Position: Q4 2021 in Review

T. Rowe Price Associates sold out of Timber Pharmaceuticals, Inc. (TMBR) in Q4 2021, closing a stake of 2,694 shares — an estimated $123K sold.

T. Rowe Price Associates first reported a position in TMBR in Q2 2021 and held it in 2 quarters. The position peaked at $123K in Q3 2021. 17 funds tracked by Wall St. Rank hold TMBR as of Q4 2021.

  • T. Rowe Price Associates reported no remaining Timber Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
  • T. Rowe Price Associates sold 2,694 Timber Pharmaceuticals, Inc. shares in Q4 2021, an estimated $123K.
  • T. Rowe Price Associates first reported a position in Timber Pharmaceuticals, Inc. in Q2 2021 and held it in 2 quarters.
  • T. Rowe Price Associates's Timber Pharmaceuticals, Inc. position peaked at $123K in Q3 2021.
  • 17 funds tracked by Wall St. Rank held Timber Pharmaceuticals, Inc. as of Q4 2021.

Based on T. Rowe Price Associates's 13F filing for Q4 2021, filed 14 Feb 2022.